KLI
Login
OAK 국가리포지터리
검색
커뮤니티
제목
저자
키워드
발행일
Ulsan Univ. Repository
Browsing by 저자 : Toni K Choueiri
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
가
나
다
라
마
바
사
아
자
차
카
타
파
하
All
가
나
다
라
마
바
사
아
자
차
카
타
파
하
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
또는 첫 단어:
정렬 기준:
제목
발행일
제출일
정렬:
오름차순
내림차순
결과 수
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
저자 수
All
1
3
5
10
15
20
25
30
35
40
45
50
전체 결과 8건 중 1-8 번을 표시중입니다.
1
Article
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
이재련
;
Aaron Hansen
;
Aly-Khan A Lalani
;
et al
2021
2
Article
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
이재련
;
Aaron Hansen
;
Aly-Khan A Lalani
;
et al
2021
3
Article
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial
이재련
;
Anders Mellemgaard
;
Anne L'Hernault
;
et al
2020
4
Article
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
이재련
;
Aaron Hansen
;
Anna Fraccon
;
et al
2021
5
Article
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
이재련
;
Aaron Hansen
;
Anna Fraccon
;
et al
2021
6
Article
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Jeffrey Graham
;
John Connor Wells
;
Shaan Dudani
;
et al
2022
7
Article
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles
;
Piotr Tomczak
;
Se Hoon Park
;
et al
2022
8
Article
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt
;
Ronald de Wit
;
Yves Fradet
;
et al
2022
1
Anonymous
Login
커뮤니티
제목
저자
키워드
발행일
Guide